Selected Publications
Lee IK, Jacome DA, Cho JK, Tu V, Young AJ, Dominguez T, Northrup JD, Etersque JM, Lee HS, Ruff A, Aklilu O, Bittinger K, Glaser LJ, Dorgan D, Hadjiliadis D, Kohli RM, Mach RH, Mankoff DA, Doot RK, Sellmyer MA: Imaging sensitive and drug-resistant bacterial infection with [11C]-trimethoprim The Journal of Clinical Investigation 132 (18): e156679,2022.
Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Kelly A, Narkewicz MR, Pittman JE, Ratjen F, Rosenfeld M, Sagel SD, Schwarzenberg SJ, Singh PK, Solomon GM, Stalvey MS, Clancy JP, Kirby S, Van Dalfsen JM, Kloster MH, Rowe SM, for the PROMISE Study group: Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial American Journal of Respiratory and Critical Care Medicine 205 (5): 529-539,2022.
Goss CH, Heltshe SL, West NE, Skalland M, Sanders DB, Jain R, Barto TL, Fogarty B, Marshall BC, VanDevanter DR, Flume PA, on Behalf of the STOP2 Investigators: A Randomized Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment American Journal of Respiratory and Critical Care Medicine 65 (1): 1295-1305,2021.
Harruff EE, Kil J, Ortiz MGT, Dorgan D, Jain R, Poth EA, Fifer RC, Kim YJM, Shoup AG, Flume PA: Ototoxicity in Cystic Fibrosis Patients Receiving Intravenous Tobramycin for Acute Pulmonary Exacerbation Journal of Cystic Fibrosis 20 (2): 288-294,2021.
Douglas JE, Civantos AM, Locke TB, Sweis AM, Hadjiliadis D, Hong G, Dorgan D, Kohanski MA, Palmer JN, Adappa ND: Impact of Novel CFTR Modulator on Sinonasal Quality of Life in Adult Patients with Cystic Fibrosis International Forum of Allergy & Rhinology 11 (2): 201-203,2021.
Rowe SW, Dorgan D, Lascano J, Zuckerman JB, McCoy K, Jain M, Schechter MS, Lommatzsch S, Indihar VM, Lechtzin N, McBennet K, Callison C, Brown C, Liou TG, MacDonald KD, Nasr SZ, Bodie S, Meltzer EB, Barbier AJ: Safety and tolerability of Single and Repeat doses of MRT5005, an inhaled CFTR mRNA replacement therapy, in adult CF patients North American Cystic Fibrosis Conference, San Antonio, TX : 2021.
Hong G, Daniel SG, Lipscombe C, Bittinger K, O’Dea A, Dorgan DJ, Hadjiliadis D: The impact of highly-effective CFTR modulation on the microbial environment in cystic fibrosis North American Cystic Fibrosis Conference, San Antonio, TX : 2021.
Chalmers JD, Haworth CS, Metersky ML, Loebinger MR, Blasi F, Sibila O, O'Donnell AE, Sullivan EJ, Mange KC, Fernandez C, Zou J, and Daley CL for the WILLOW Investigators: Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis New England Journal of Medicine 383 (22): 2127-2137,2020.
Krymskaya VP, Courtwright AM, Fleck V, Dorgan D, Kotloff R, McCormack FX, Kreider M: A phase II clinical trial of the Safety of Simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex Respiratory Medicine 163 : 105898 (ePub),2020.
Hong G, Alby K, Ng SCW, Fleck V, Kubrak C, Rubenstein RC, Dorgan DJ, Kawut SM, Hadjiliadis D: The Presence of Aspergillus fumigatus is Associated with Worse Respiratory Quality of Life in Cystic Fibrosis Journal of Cystic Fibrosis 19 (1): 125-130,2020.
Academic Contact Information
Harron Lung Center
3400 Civic Center Blvd
Philadelphia,
PA
19104
Phone: 215-662-3202
Patient appointments: 800-789-7366